Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A international phase 3 study of Lupuzor for the treatment of systemic lupus erythematosus

Next Previous
Search
Trial Profile

A international phase 3 study of Lupuzor for the treatment of systemic lupus erythematosus

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 24 Jun 2021 According to an ImmuPharma media release, company will provide an update as soon as Avion has received the written response from the FDA and advised ImmuPharma of the next steps and timetable towards commencing the Phase 3 trial this year.
    • 24 Jun 2021 According to an ImmuPharma media release,as noted in our previous announcement of 9 February, this is the final guidance meeting at which the FDA will review the proposed methodology of the pharmacokinetic ("PK") study. This study was requested by the FDA as part of the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus.
    • 24 Jun 2021 According to an ImmuPharma media release, company, announces that its US Lupuzor™ partner, Avion Pharmaceuticals ("Avion") has received a positive response from the US Food & Drug Administration ("FDA") for a "Type C" meeting. The FDA has advised that they do not require a formal face to face meeting and will provide their written response to Avion approximately by the end of July 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top